colorectal cancer
| 3 min read
Ryvu’s ONCO Prime platform uncovers novel molecular vulnerabilities and actionable targets in colorectal and other cancers.
| 3 min read
Final results from the AMPLIFY-201 phase 1 trial highlight durable T cell responses and prolonged survival in patients with colorectal and pancreatic cancer.
| 5 min read
Methylation profiling of cell-free DNA is opening new possibilities for detecting cancer at its earliest, pre-symptomatic stages, offering a potential breakthrough in how and when disease is found.
| 5 min read
Initially thought of as a DNA-damaging drug, 5-fluorouracil mainly kills cancer cells by interfering with ribosomal RNA, opening up new avenues for care.
Page 1 of 1 - 4 Total Items
